Revisiting the bipolar disorder with migraine phenotype: Clinical features and comorbidity
Por:
Romo-Nava F., Blom T., Cuellar-Barboza A.B., Awosika O.O., Martens B.E., Mori N.N., Colby C.L., Prieto M.L., Veldic M., Singh B., Gardea-Resendez M., Nunez N.A., Ozerdem A., Biernacka J.M., Frye M.A., McElroy S.L.
Publicada:
1 ene 2021
Resumen:
Introduction: To evaluate the prevalence and clinical correlates of lifetime migraine among patients with bipolar disorder (BD). Methods: In a cross-sectional study, we evaluated 721 adults with BD from the Mayo Clinic Bipolar Disorder Biobank and compared clinical correlates of those with and without a lifetime history of migraine. A structured clinical interview (DSM-IV) and a clinician-assessed questionnaire were utilized to establish a BD diagnosis, lifetime history of migraine, and clinical correlates. Results: Two hundred and seven (29%) BD patients had a lifetime history of migraine. BD patients with migraine were younger and more likely to be female as compared to those without migraine (p values <0.01). In a multivariate logistic regression model, younger age (OR=0.98, p<0.01), female sex (OR=2.02, p<0.01), higher shape/weight concern (OR=1.04, p=0.02), greater anxiety disorder comorbidities (OR=1.24, p<0.01), and evening chronotype (OR=1.65, p=0.03) were associated with migraine. In separate regression models for each general medical comorbidity (controlled for age, sex, and site), migraines were significantly associated with fibromyalgia (OR=3.17, p<0.01), psoriasis (OR=2.65, p=0.03), and asthma (OR=2.0, p<0.01). Participants with migraine were receiving ADHD medication (OR=1.53, p=0.05) or compounds associated with weight loss (OR=1.53, p=0.02) at higher rates compared to those without migraine. Limitations: Study design precludes determination of causality. Migraine subtypes and features were not assessed. Conclusions: Migraine prevalence is high in BD and is associated with a more severe clinical burden that includes increased comorbidity with pain and inflammatory conditions. Further study of the BD-migraine phenotype may provide insight into common underlying neurobiological mechanisms. © 2021
Filiaciones:
Romo-Nava F.:
Lindner Center of HOPE, Mason, OH, United States
Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, United States
Blom T.:
Lindner Center of HOPE, Mason, OH, United States
Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, United States
Cuellar-Barboza A.B.:
Department of Psychiatry, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico
Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, United States
Awosika O.O.:
Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States
Martens B.E.:
Lindner Center of HOPE, Mason, OH, United States
Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, United States
Mori N.N.:
Lindner Center of HOPE, Mason, OH, United States
Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, United States
Colby C.L.:
Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States
Prieto M.L.:
Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, United States
Department of Psychiatry, Faculty of Medicine, Universidad de los Andes, Santiago, Chile
Mental Health Service, Clínica Universidad de los Andes, Santiago, Chile
Center for Biomedical Research and Innovation, Universidad de los Andes, Santiago, Chile
Veldic M.:
Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, United States
Singh B.:
Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, United States
Gardea-Resendez M.:
Department of Psychiatry, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico
Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, United States
Nunez N.A.:
Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, United States
Ozerdem A.:
Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, United States
Biernacka J.M.:
Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, United States
Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States
Frye M.A.:
Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, United States
McElroy S.L.:
Lindner Center of HOPE, Mason, OH, United States
Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, United States
|